# The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome

> **NCT00626418** · PHASE2 · COMPLETED · sponsor: **Ligand Pharmaceuticals** · enrollment: 24 (estimated)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DRUG:** Aplindore
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00626418
- **Lead sponsor:** Ligand Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-10
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2011-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00626418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00626418, "The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00626418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*